Federal Circuit Affirms Minocin Patents, Bolstering CorMedix's Hospital Portfolio

What happened

The U.S. Court of Appeals for the Federal Circuit has upheld a district court ruling that CorMedix's Minocin patents are valid and infringed by Nexus Pharmaceuticals, protecting a key asset in the Melinta hospital anti-infective portfolio. While this removes a near-term competitive threat for Minocin, the ruling does not alter the central investment thesis, which hinges on DefenCath utilization growth ahead of its July 2026 reimbursement step-down. CorMedix’s FY2026 guidance of $300M–$320M revenue and $100M–$125M adjusted EBITDA already assumes sustained Melinta contributions, and the patent victory merely validates that assumption without expanding it. The market has largely priced in the DefenCath reimbursement risk, and this legal win provides minor downside protection for the base-case scenario. Overall, the news reduces one uncertainty but leaves the primary revenue cliff and pipeline catalysts as the dominant drivers over the next 6–12 months.

Implication

The ruling strengthens CorMedix's hospital franchise and supports the Melinta synergy story, but the stock's re-rating depends on DefenCath adoption KPIs (due Feb 2026) and REZZAYO Phase 3 data. Investors should view this as incremental validation, not a thesis-changer.

Thesis delta

The patent win slightly de-risks Melinta revenue but does not move the needle on DefenCath's utilization trajectory or the July 2026 TDAPA step-down. The investment case remains a bet on front-loaded 1H26 DefenCath growth and Melinta cost synergies offsetting a known 2H26 pricing reset. No material shift in probability-weighted scenarios; base case of $9 and bear case of $5 remain intact.